Abstrakt
Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.
Bidragets oversatte titel | Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom |
---|---|
Originalsprog | Engelsk |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 184 |
Udgave nummer | 42 |
ISSN | 0041-5782 |
Status | Udgivet - 17 okt. 2022 |
Emneord
- Humans
- Non-alcoholic Fatty Liver Disease/diagnosis
- Liver Cirrhosis/complications
- Biopsy
- Fibrosis
- Referral and Consultation
- Liver/pathology